Highlights

  • Protara priced an underwritten public offering of 13.04 million common shares at USD 5.75 each.
  • Gross proceeds are expected to be around USD 75 million before standard offering deductions.
  • Net funds are earmarked for clinical development programs and general corporate purposes.

Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company focused on therapies for cancer and rare diseases, announced the pricing of its underwritten public offering of common stock. The offering comprises 13,043,479 shares, which were priced at USD 5.75 per share. All shares included in the transaction are being issued and sold by the company.

The company has also granted the underwriters a 30-day option to purchase up to an additional 1,956,521 shares at the same public offering price, less applicable underwriting discounts and commissions. Any exercise of this option would increase the total number of shares sold as part of the transaction.

Expected Proceeds and Use of Funds

Gross proceeds from the base offering are expected to total approximately USD 75 million, prior to deductions for underwriting discounts, commissions, and other offering-related expenses. The proceeds figure does not include any potential funds generated from the exercise of the underwriters’ option.

According to the company, the net proceeds are intended to be used primarily to fund the clinical development of TARA-002. In addition, Protara may allocate funds toward the advancement of other clinical-stage programs within its pipeline. A portion of the proceeds may also be used for working capital requirements and other general corporate purposes.

Timeline and Regulatory Framework

The public offering is expected to close on December 8, 2025, subject to the completion of customary closing conditions. The shares are being issued under an existing shelf registration statement on Form S-3 that was previously declared effective by the U.S. Securities and Exchange Commission in November 2023.

The sale of securities is being conducted through a prospectus supplement and an accompanying prospectus filed with the SEC. These documents provide detailed information regarding the terms of the offering, associated risks, and the company’s business and financial condition.

Underwriting Syndicate

J.P. Morgan, TD Cowen, and Piper Sandler are acting as joint book-running managers for the offering. LifeSci Capital is serving as lead manager, while H.C. Wainwright & Co. is acting as a manager. Each firm is participating in the distribution of shares in accordance with standard underwriting practices.

Share Performance
The stock closed at USD 6.87 on December 4, 2025, gaining 1.03%, during the trading session, after opening at USD 6.69 and moving between an intraday high of USD 7.05 and a low of USD 6.65. The company has a market capitalisation of USD 26.51 Cr and has traded between a 52-week high of USD 10.48 and a 52-week low of USD 2.77.